Embla Medical posted its financial results for the third quarter (3Q).
Highlights included:
- Sales amounted to $250 million, growing by 4 percent organically and 5 percent reported and in local currencies.
- Organic sales growth by segment: prosthetics and neuro orthotics was plus 7 percent, bracing and supports was plus 2 percent, patient care was zero.
- Gross profit margin was 62 percent, compared with 63 percent in 3Q 2025.
- Earnings before interest, taxes, depreciation, and amortization (EBITDA) totaled $56 million, corresponding to a margin of 22 percent of sales, on par with 3Q in 2025.
- Net profit amounted to $26 million, corresponding to a net profit margin of 10 percent, compared with 11 percent in 3Q 2025.
- Free cash flow totaled $31 million, or 12 percent of sales, compared with 16 percent of sales during the same period in 2025.
- Net-bearing interest debt/EBITDA before special items was 2.1x, which was within the company’s target range of 2-3x EBITDA. The company repurchased 635,267 shares with a market value of $2.8 million.
